scholarly journals Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

2012 ◽  
Vol 367 (18) ◽  
pp. 1714-1723 ◽  
Author(s):  
Steven Boonen ◽  
Jean-Yves Reginster ◽  
Jean-Marc Kaufman ◽  
Kurt Lippuner ◽  
Jose Zanchetta ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Fracture Risk ◽  
Acid Therapy

scholarly journals EFFECT OF ZOLEDRONIC ACID THERAPY ON FRACTURE RISK IN THE TREATMENT OF MEN WITH OSTEOPOROSIS

2012 ◽  
Vol 15 (3) ◽  
pp. 40-40
Author(s):  
Steven Boonen ◽  
Jean-Yves Reginster ◽  
Jean-Marc Kaufman
Keyword(s):  
Zoledronic Acid ◽  
Fracture Risk ◽  
Acid Therapy

scholarly journals Safety & Efficacy of Cyclic Zoledronic Acid Therapy on Pediatric Secondary Osteoporosis

2015 ◽  
Vol 8 (8) ◽  
pp. 20
Author(s):  
Abdulmoein E. Al-Agha ◽  
Talal A. Shaikhain ◽  
Abdullah A. Ashour
Keyword(s):  
Zoledronic Acid ◽  
Children And Adolescents ◽  
Pediatric Patients ◽  
Systemic Disease ◽  
Laboratory Data ◽  
University Hospital ◽  
Secondary Osteoporosis ◽  
Fracture Rate ◽  
Acid Therapy ◽  
Positive Effects

<p class="NormalWeb"><strong>BACKGROUND/AIM:</strong> Osteoporosis is a systemic disease characterized by decreased bone density and increased tendency to develop fractures. Osteoporosis in children and adolescents is a rare disease usually secondary to Medical conditions or medications given to children. The condition affects normal bone growth and development and carries with it multiple morbidities (physical and psychological) if not corrected promptly. This study aims to share our experience with Zoledronic Acid Therapy in Pediatric patients with secondary osteoporosis.</p><p class="NormalWeb"><strong>METHOD:</strong> A retrospective study which included 46 patients aged 3 to 18 years. All patients received specific doses of Zoledronic acid and were followed up at King Abdulaziz University Hospital (KAUH) in Jeddah, Saudi Arabia. Clinical and laboratory data were collected for each patient from their files. Adverse events were also recorded.</p><p class="NormalWeb"><strong>RESULTS:</strong> The use of Zoledronic Acid in children and adolescents appears to be statically significant reduce fracture rate (p=0.005), bone turnover markers (Osteocalcin p= 0.003, CTX p= 0.008) and pain frequency in symptomatic individuals (p=0.000). Careful selection of cases is required to provide maximum benefits compared to risks associated with therapy.</p><p class="NormalWeb"><strong>CONCLUSION:</strong> This study demonstrates that Zoledronic acid has positive effects on clinical outcome and bone marker level as well as quality of life for Pediatric patients with Osteoporosis and their families, with no long-term side effects.</p>

scholarly journals Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?

2014 ◽  
Vol 99 (12) ◽  
pp. 4546-4554 ◽  
Author(s):  
Felicia Cosman ◽  
Jane A. Cauley ◽  
Richard Eastell ◽  
Steven Boonen ◽  
Lisa Palermo ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Fracture Risk ◽  
Discontinue Treatment
Sign in / Sign up

Export Citation Format

Share Document